HC Wainwright Reduces Earnings Estimates for AngioDynamics

AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) - Equities research analysts at HC Wainwright cut their Q1 2026 earnings per share estimates for shares of AngioDynamics in a research report issued to clients and investors on Wednesday, July 16th. HC Wainwright analyst Y. Chen now anticipates that the medical instruments supplier will post earnings of ($0.14) per share for the quarter, down from their previous forecast of ($0.12). HC Wainwright has a "Buy" rating and a $16.00 price objective on the stock. The consensus estimate for AngioDynamics' current full-year earnings is ($0.37) per share. HC Wainwright also issued estimates for AngioDynamics' Q2 2026 earnings at ($0.10) EPS, Q3 2026 earnings at ($0.08) EPS, Q4 2026 earnings at $0.02 EPS and FY2026 earnings at ($0.30) EPS.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last released its earnings results on Tuesday, July 15th. The medical instruments supplier reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.09. The company had revenue of $80.16 million during the quarter, compared to the consensus estimate of $74.26 million. AngioDynamics had a negative return on equity of 3.20% and a negative net margin of 11.62%. AngioDynamics's revenue was up 13.0% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.06) EPS.

Several other equities research analysts have also recently weighed in on ANGO. Lake Street Capital assumed coverage on AngioDynamics in a research note on Wednesday, July 16th. They set a "buy" rating and a $24.00 target price for the company. Canaccord Genuity Group set a $17.00 target price on AngioDynamics and gave the stock a "buy" rating in a research note on Wednesday, July 16th.

AngioDynamics Stock Performance

Shares of ANGO traded up $0.19 during midday trading on Friday, hitting $8.88. The company had a trading volume of 189,220 shares, compared to its average volume of 658,047. The company's 50-day simple moving average is $9.86 and its 200-day simple moving average is $10.08. The firm has a market capitalization of $360.41 million, a P/E ratio of -10.69 and a beta of 0.60. AngioDynamics has a 1 year low of $5.83 and a 1 year high of $13.50.

Institutional Investors Weigh In On AngioDynamics

Several large investors have recently modified their holdings of the stock. Assenagon Asset Management S.A. increased its position in shares of AngioDynamics by 30.4% in the second quarter. Assenagon Asset Management S.A. now owns 312,707 shares of the medical instruments supplier's stock valued at $3,102,000 after buying an additional 72,826 shares in the last quarter. Strs Ohio acquired a new stake in shares of AngioDynamics during the first quarter worth approximately $514,000. Jane Street Group LLC raised its position in shares of AngioDynamics by 267.1% during the 1st quarter. Jane Street Group LLC now owns 46,803 shares of the medical instruments supplier's stock valued at $439,000 after acquiring an additional 34,054 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in AngioDynamics by 9.6% in the first quarter. Goldman Sachs Group Inc. now owns 259,226 shares of the medical instruments supplier's stock valued at $2,434,000 after buying an additional 22,658 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. bought a new position in shares of AngioDynamics in the first quarter worth $939,000. Hedge funds and other institutional investors own 89.43% of the company's stock.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.